Allogeneic HCT still plays an important role in the treatment of CLL, particularly for eligible patients with high-risk genetic features and those with resistance to Bruton tyrosine kinase (BTK) and/or B-cell lymphoma-2 (BCL2) inhibitors who have limited other therapeutic options (3). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.